FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

CBER Offers Tips for Cell/Gene Therapy BLA Submissions

[ Price : $8.95]

CBER recently used a virtual town hall to urge developers of cell and gene therapies to take advantage of early engagements with t...

FDA Urges Broader Eligibility for Cancer Clinical Trials

[ Price : $8.95]

An FDA final guidance encourages sponsors of oncology clinical trials to broaden eligibility criteria by including more patients w...

Reviewers Question Data on Capricor's Duchenne Cardiomyopathy Cell Therapy

[ Price : $8.95]

FDA reviewers raise issues with Capricor Therapeutics resubmitted deramiocel for treating cardiomyopathy in male patients with Duc...

Amgen New Data Pushes Back Against Proposal to Withdraw Tavneos

[ Price : $8.95]

Amgen files new scientific data and analyses in its bid to prevent FDA withdrawal of Tavneos (avacopan), arguing that the treatmen...

FDA Rejects Apiject's NDA for Glycopyrrolate Combination Product

[ Price : $8.95]

FDA issues a Complete Response Letter to Apiject Systems Corp., declining to approve the company's NDA for a glycopyrrolate soluti...

FDA Early Alert Over Boston Scientific Transcarotid Catheter Systems

[ Price : $8.95]

FDA issues an early alert warning about a potentially high-risk issue involving certain lots of Boston Scientific's ENROUTE Transc...

FDA Advisers Back Expanded Access to Several Compounded Peptides

[ Price : $8.95]

An FDA advisory committee 7/23 voted to recommend allowing several controversial peptides to be considered for inclusion on the ag...

FDA cites Bausch + Lomb Manufacturing Facility

[ Price : $8.95]

FDA cites Bausch + Lomb for GMP deficiencies following a 3/12-20 inspection of the company's sterile drug manufacturing facility i...

Lillys Retatrutide Hits Endpoint in 2 Trials

[ Price : $8.95]

Lilly says its triple hormone receptor agonist retatrutide met the primary weight loss endpoint in two Phase 3 trials.

FDA Should Ban DTC Drug Ads: Public Citizen

[ Price : $8.95]

Advocacy group Public Citizen files a petition urging FDA to ban prescription drug direct-to-consumer advertising.